180 related articles for article (PubMed ID: 2907912)
1. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors.
Hess EJ; Norman AB; Creese I
J Neurosci; 1988 Jul; 8(7):2361-70. PubMed ID: 2907912
[TBL] [Abstract][Full Text] [Related]
2. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
3. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
Giorgi O; Biggio G
Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
[TBL] [Abstract][Full Text] [Related]
4. Age-dependent differences in the rate of recovery of striatal dopamine D1 and D2 receptors after inactivation with EEDQ.
Crawford CA; Rowlett JK; McDougall SA; Bardo MT
Eur J Pharmacol; 1994 Feb; 252(2):225-31. PubMed ID: 8157063
[TBL] [Abstract][Full Text] [Related]
5. Dopamine receptor reappearance after irreversible receptor blockade: effect of chronic estradiol treatment of ovariectomized rats.
Lévesque D; Di Paolo T
Mol Pharmacol; 1991 May; 39(5):659-65. PubMed ID: 1674586
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics.
Meller E; Bohmaker K; Goldstein M; Friedhoff AJ
J Pharmacol Exp Ther; 1985 Jun; 233(3):656-62. PubMed ID: 2861276
[TBL] [Abstract][Full Text] [Related]
7. Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro.
Hess EJ; Battaglia G; Norman AB; Creese I
Mol Pharmacol; 1987 Jan; 31(1):50-7. PubMed ID: 3100940
[TBL] [Abstract][Full Text] [Related]
8. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine.
Burger LY; Martin-Iverson MT
Synapse; 1993 Jan; 13(1):20-9. PubMed ID: 8093985
[TBL] [Abstract][Full Text] [Related]
9. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.
Xu SX; Hatada Y; Black LE; Creese I; Sibley DR
J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530
[TBL] [Abstract][Full Text] [Related]
10. Importance of D1 and D2 receptor stimulation for the induction and expression of cocaine-induced behavioral sensitization in preweanling rats.
McDougall SA; Rudberg KN; Veliz A; Dhargalkar JM; Garcia AS; Romero LC; Gonzalez AE; Mohd-Yusof A; Crawford CA
Behav Brain Res; 2017 May; 326():226-236. PubMed ID: 28284952
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
Hamblin MW; Creese I
Life Sci; 1983 May; 32(19):2247-55. PubMed ID: 6133202
[TBL] [Abstract][Full Text] [Related]
12. Unilateral inactivation of dopamine receptors after intrastriatal injection of N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): a novel rotational model to investigate dopamine receptor interactions.
Giorgi O; Biggio G
Pharmacol Biochem Behav; 1990 Apr; 35(4):877-84. PubMed ID: 1971721
[TBL] [Abstract][Full Text] [Related]
13. Lesions of mouse striatum induced by 6-hydroxydopamine differentially alter the density, rate of synthesis, and level of gene expression of D1 and D2 dopamine receptors.
Qin ZH; Chen JF; Weiss B
J Neurochem; 1994 Feb; 62(2):411-20. PubMed ID: 8294904
[TBL] [Abstract][Full Text] [Related]
14. An autoradiographic study of the differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on striatal and extrastriatal D-1 and D-2 dopamine receptors in the rat.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Neuropharmacology; 1994 May; 33(5):647-55. PubMed ID: 7936100
[TBL] [Abstract][Full Text] [Related]
15. Alterations in the turnover rate of dopamine D1 but not D2 receptors in the adult rat neostriatum after a neonatal dopamine denervation.
Dewar KM; Paquet M; Reader TA
Neurochem Int; 1997 Jun; 30(6):613-21. PubMed ID: 9153003
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the selectivities of SCH 23390 with BW737C89 for D1, D2 and 5-HT2 binding sites both in vitro and in vivo.
Riddall DR
Eur J Pharmacol; 1992 Jan; 210(3):279-84. PubMed ID: 1351844
[TBL] [Abstract][Full Text] [Related]
17. Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms.
Norman AB; Battaglia G; Creese I
J Neurosci; 1987 May; 7(5):1484-91. PubMed ID: 2952771
[TBL] [Abstract][Full Text] [Related]
18. Tyr-MIF-1 attenuates development of tolerance to spiperone-induced catalepsy in rats.
Kostrzewa RM; Kastin AJ
Brain Res Bull; 1993; 31(6):707-12. PubMed ID: 8100182
[TBL] [Abstract][Full Text] [Related]
19. Guanine nucleotide regulation of agonist interactions at [3H]SCH23390-labeled D1 dopamine receptors in rat striatum.
Hess EJ; Battaglia G; Norman AB; Iorio LC; Creese I
Eur J Pharmacol; 1986 Feb; 121(1):31-8. PubMed ID: 2869957
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of SCH 23390-induced alteration of striatal dopamine D1 receptor ontogeny by prolyl-leucyl-glycinamide in the rat.
Kostrzewa RM; Saleh MI
Neuropharmacology; 1989 Aug; 28(8):805-10. PubMed ID: 2571103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
